column one second transplant revolut new gener anti reject chemic appear potent select may make organ replac even routin everi week last year 30 liver heart transplant unit state oper quit liter gave patient month year extra life eight year ago 62 liver 103 heart transplant entir year sharp increas result discoveri anti reject drug call cyclosporin make transplant safer effect revolution field transplant surgeri point major organ transplant everi 40 minut unit state today surgeon experi new gener anti reject drug may alter field everi bit much cyclosporin drug potent cyclosporin prevent reject far least seem fewer side effect also cheaper insignific consider drug must taken remaind person life import new drug seem select pinpoint suppress portion immun system attack organ leav rest free fight infect dr han solling transplant surgeon univers wisconsin madison predict use transplant drug soon bear strong resembl current situat antibiot physician choos among 20 drug treat certain type infect certain type patient forese time futur determin type reject immun cell type involv forth open drawer select proper drug given organ given type reject said result transplant becom even routin peopl defect organ abl receiv replac replac last longer darker side howev develop increas demand donor organ alreadi short suppli 19 000 american wait list donor heart kidney organ increas success rate make demand even larger attempt transplant record long ago egyptian manuscript written 2000 bc 1940 scientist comprehend success carri transplant period late nobel laureat sir peter brian medawar oxford univers demonstr definit transplant failur caus immun system protect bodi infect base medawar work research realiz necessari stop immun system attack implant organ would diseas caus bacterium unfortun techniqu avail suppress immun system whole bodi irradi destroy immun system cell sever kidney transplant attempt use techniqu kidney surviv patient succumb infect first success kidney transplant achiev 1954 harvard surgeon joseph e murray use steroid hormon suppress inflamm part reject process steroid suppress immun system effect forc use organ live donor close relat recipi late 1960 chemist georg hitch burrough wellcom co synthes deriv cancer drug strongli suppress immun system drug call azathioprin imuran made transplant practic use conjunct steroid develop made possibl first heart lung liver pancrea transplant none transplant procedur success 65 patient much less success furthermor imuran broad suppress immun system left patient suscept varieti infect well increas risk cancer normal kept check immun system situat chang dramat 1970 discoveri cyclosporin fungu southern norway immunologist jean borel swiss pharmaceut firm sandoz ltd show suppress part immun system specif one type white blood cell lymphocyt call helper cell specul drug thu could reduc chanc reject leav immun system intact fight infect surgeon began use cyclosporin earli 1980 never went back imuran stanford univers two year surviv rate heart transplant jump 63 83 1985 kidney transplant throughout unit state period one year surviv rate leap 60 80 liver transplant show dramat increas one year surviv rate doubl 70 transplant oper flower never cyclosporin unfortun side effect well critic damag kidney lower clearanc wast blood suprem ironi drug made kidney transplant success also greatli improv surviv rate first year fewer 70 organ surviv first year surviv second note stanford immunologist randal c morri practic term attrit mean mani patient perhap mani half kidney recipi come back second third even fourth organ research morri studi number new drug think chang curv better one thoroughli studi far call fk506 fk506 discov 1984 research fujisawa pharmaceut co soil sampl taken coupl mile laboratori tsukuba japan use morri describ extrem sophist still larg secret system screen soil water sampl look anti reject drug first agent found accid new chemic belong class bacteri product call macrolid famili includ commonli prescrib antibiot erythromycin fujisawa scientist found fk506 30 time potent cyclosporin suppress immun system meant potenti could given much smaller dose minim side effect fk506 almost never use human immunologist roy caln cambridg univers england found toxic dog report british journal lancet caus mani research abandon studi surgeon thoma e starzl univers pittsburgh medic center found toxic vari speci speci import found drug could greatli extend surviv transplant anim dog could rescu organ suffer acut reject episod februari 1989 28 year old robin ford brought univers hospit pittsburgh undergo acut kidney reject starzl decid use fk506 conjunct cyclosporin tri rescu organ combin prove extrem toxic ford starzl took gambl stop use cyclosporin fk506 stop reject episod unfortun cyclosporin alreadi destroy ford kidney receiv fk506 along second donor organ back work first time two year import starzl seen potenti drug starzl use drug 300 liver kidney transplant patient uniformli good result interestingli morri said drug halt reject episod also stimul regrowth repair damag liver cell drug morri said starzl said patient receiv drug leav hospit within two week liver transplant half recuper time requir cyclosporin also fewer reject episod infect far least side effect improv recuper time starzl predict cost liver transplant reduc least one third current level 200 000 cost reduct also achiev type transplant clinic trial drug medic center expect begin shortli varieti drug promis improv fk506 studi stanford elsewher speed research drug morri develop innov techniqu take small piec heart tissu one strain mous place cartilag skin ear mice differ strain blood vessel grow heart tissu within four six day muscl tissu begin beat although pump blood treat recipi reject 10 day said treat new drug see long heart beat realli speed process drug discoveri develop drug appear promis test rat monkey trial human test head head like make clear distinct among see role said one new drug morri consid promis rapamycin close rel fk506 discov 1970 research ayerst laboratori canada look antibiot fight yeast infect rapamycin good antibiot morri said also interf immun system shelv properti plu fact molecular structur much like fk506 prompt morri evalu anti reject drug expect much differ fk506 morri said surpris rat potent 60 time potent cyclosporin twice potent fk506 potent drug ever seen morri hope begin test rapamycin primat year morri high hope anoth drug call rs 61443 oper complet differ mechan fk506 macrolid thu may abl interven differ stage reject morri test rs 61443 three anim system mice rat monkey found could prevent reject revers advanc reject particularli promis said wisconsin solling also test dog combat chronic reject none avail drug solling use drug routin use treat skin diseas psoriasi first time human transplant patient april research univers alabama plan studi kidney transplant patient morri said stanford team plan test rs 61443 heart transplant patient perhap earli summer two drug deserv mention one deoxyspergualin bacteri product impress fk506 speci particularli primat said surgeon robert corri univers iowa medic center deoxyspergualin alreadi use success small number kidney transplant japan kidney pancrea transplant europ corri head group u investig plan begin test drug human summer test group consist patient receiv second kidney deal popul 60 success rate rather 90 case first kidney transplant said success clear cut would patient alreadi pretti well drug attract interest new one larg discredit 25 year ago thalidomid develop tranquil sleep aid use abandon caus unusu sever limb deform almost 12 000 european children whose mother took drug pregnant drug never approv use unit state research john hopkin school medicin baltimor find use treat recipi bone marrow transplant use treatment certain type cancer chronic myelogen leukemia transplant unusu transplant organ bone marrow sourc lymphocyt thu part immun system transplant goe bad bodi reject transplant transplant organ reject bodi graft versu host diseas affect nearli half 2 000 cancer patient receiv bone marrow transplant year caus sever damag recipi tissu even death thalidomid said oncologist georgia b vogelsang hopkin drug shown revers graft versu host diseas anim start vogelsang colleagu treat 100 patient thalidomid success revers graft versu host diseas 60 half case note drug absorb patient bodi thu never chanc function signific side effect observ vogelsang said sleepi mild constip birth defect problem radiat use destroy patient bone marrow transplant steril recipi research still know complet expect new drug still infanc thing corri said hold high hope futur main messag peopl need transplant hope patienc nice therapeut morri said realli light end tunnel